Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vicore Pharma Holding AB ( (SE:VICO) ) has issued an update.
Vicore Pharma Holding AB announced its participation in Pareto Securities’ 16th Annual Healthcare Conference in Stockholm, where CFO Hans Jeppsson and CMO Bertil Lindmark will present and engage in one-on-one meetings. This participation underscores Vicore’s ongoing efforts to advance its novel drug class in the pharmaceutical industry, potentially enhancing its market presence and stakeholder engagement.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a novel class of drugs, particularly angiotensin II type 2 receptor agonists (ATRAGs), for treating respiratory and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). Its lead program, buloxibutid (C21), is an oral small molecule that has received Orphan Drug and Fast Track designation from the FDA and is in a Phase 2b trial.
YTD Price Performance: 31.12%
Average Trading Volume: 550,079
Technical Sentiment Signal: Hold
Current Market Cap: SEK2.6B
Find detailed analytics on VICO stock on TipRanks’ Stock Analysis page.